Lipocine Inc.

XNAS

Last traded price · USD

$1.42

−1.39%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:30 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $1.44
Volume: 1,095
Day's high: —
Day's low: —

In brief

Lipocine Inc. is a US-listed company listed on Nasdaq, valued at about $12M.
Its shares closed at $1.44 on 4 Nov 2026, down 43.1% over the past year.
From India you can buy LPCN in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Lipocine Inc. (LPCN) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole LPCN share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade LPCN options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY over 1 year
1 month: −31.4% (SPY −1.6%). 3 months: −33.6% (SPY −0.4%). 1 year: −43.1% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: LPCN, SPY · as of 4 Nov 2026
5.9% above its 52-week low
Closed at $1.44 on 4 Nov 2026: 88.4% below the 52-week high of $12.37 (15 Jan 2026) and 5.9% above the low of $1.36 (2 Nov 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $1.44 was 26.0% below its 50-day average ($1.95) and 61.8% below its 200-day average ($3.77). It has closed below the 200-day for 150 sessions, since 2 Apr 2026. The 50-day average crossed below the 200-day on 12 May 2026, 122 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Short interest at 4.3% of shares outstanding
351.4K shares were sold short at the 15 Oct 2026 settlement, 4.3% of the 8.2M shares outstanding; covering them would take 1.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−31.4%

6 months−40.7%

1 year−43.1%

5 years−92.8%

Newswire

About

Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Website

Notable moves

April 2, 2026
−77.84%
June 18, 2024
−32.83%
May 23, 2023
+32.27%

Newswire

About

Website

Notable moves

April 2, 2026
−77.84%
June 18, 2024
−32.83%
May 23, 2023
+32.27%

Lipocine Inc.

XNAS

Last traded price · USD

$1.42

−1.39%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:30 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $1.44
Volume: 1,095
Day's high: —
Day's low: —

In brief

Lipocine Inc. is a US-listed company listed on Nasdaq, valued at about $12M.
Its shares closed at $1.44 on 4 Nov 2026, down 43.1% over the past year.
From India you can buy LPCN in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Lipocine Inc. (LPCN) shares from India?

Do I need the price of a whole LPCN share to invest?

How much can I invest in US stocks in a year?

Can I trade LPCN options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY over 1 year
1 month: −31.4% (SPY −1.6%). 3 months: −33.6% (SPY −0.4%). 1 year: −43.1% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: LPCN, SPY · as of 4 Nov 2026
5.9% above its 52-week low
Closed at $1.44 on 4 Nov 2026: 88.4% below the 52-week high of $12.37 (15 Jan 2026) and 5.9% above the low of $1.36 (2 Nov 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $1.44 was 26.0% below its 50-day average ($1.95) and 61.8% below its 200-day average ($3.77). It has closed below the 200-day for 150 sessions, since 2 Apr 2026. The 50-day average crossed below the 200-day on 12 May 2026, 122 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Short interest at 4.3% of shares outstanding
351.4K shares were sold short at the 15 Oct 2026 settlement, 4.3% of the 8.2M shares outstanding; covering them would take 1.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−31.4%

6 months−40.7%

1 year−43.1%

5 years−92.8%

Newswire

About

Website

Notable moves

April 2, 2026
−77.84%
June 18, 2024
−32.83%
May 23, 2023
+32.27%

Newswire

About

Website

Notable moves

April 2, 2026
−77.84%
June 18, 2024
−32.83%
May 23, 2023
+32.27%

Lipocine Inc.

Lipocine Inc. in brief

Behind SPY over 1 year

5.9% above its 52-week low

Below its 50- and 200-day averages

Short interest at 4.3% of shares outstanding

Lipocine Inc.

Lipocine Inc. in brief

Behind SPY over 1 year

5.9% above its 52-week low

Below its 50- and 200-day averages

Short interest at 4.3% of shares outstanding